FIGURE

Fig. 5

ID

ZDB-FIG-211009-28

Publication

He et al., 2021 - Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss

Other Figures

All Figure Page

Back to All Figure Page

Fig. 5

Sirolimus induces a durable cytostatic effect in <italic>nf1/pten</italic>-mutant melanomas.

a Representative tissue sections from a transplanted nf1/pten-mutant melanoma tumor at 4 days after a 6-day drug treatment with DMSO (CTR), 80 nM trametinib, 2 μM buparlisib, the combination of 80 nM trametinib and 2 μM buparlisib, or 20 μM sirolimus. Sections were immunostained using antibodies to detect pERK, pAKT, pS6, PCNA, and CC3. pERK-, pAKT- and pS6-positive tumor areas, as well as PCNA-positive nuclei, are quantified in (b–e). “T + B” refers to trametinib plus buparlisib. ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.0001 by Mann–Whitney test. Scale bar = 20 μm.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Oncogene